Literature DB >> 34536078

Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations.

Ryan C Ungaro1, Jean-Frederic Colombel1, Marla C Dubinsky1, Anjali Jain2, Thierry Dervieux2.   

Abstract

Entities:  

Keywords:  drug monitoring; immunogenicity; infliximab; thiopurine

Mesh：

Substances：

Year:  2022        PMID： 34536078      PMCID： PMC9122746          DOI： 10.1093/ibd/izab232

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   7.290


× No keyword cloud information.
  9 in total

Review 1.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Authors:  Joseph D Feuerstein; Geoffrey C Nguyen; Sonia S Kupfer; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-08-03       Impact factor: 22.682

2.  Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.

Authors:  Andres J Yarur; Maddie J Kubiliun; Frank Czul; Daniel A Sussman; Maria A Quintero; Anjali Jain; Katherine A Drake; Scott I Hauenstein; Steven Lockton; Amar R Deshpande; Jamie S Barkin; Sharat Singh; Maria T Abreu
Journal:  Clin Gastroenterol Hepatol       Date:  2015-01-03       Impact factor: 11.382

3.  Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.

Authors:  Jean-Frédéric Colombel; Omoniyi J Adedokun; Christopher Gasink; Long-Long Gao; Freddy J Cornillie; Geert R D'Haens; Paul J Rutgeerts; Walter Reinisch; William J Sandborn; Stephen B Hanauer
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-26       Impact factor: 11.382

4.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

Review 5.  Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.

Authors:  Jose Ramon Maneiro; Eva Salgado; Juan Jesus Gomez-Reino
Journal:  JAMA Intern Med       Date:  2013-08-12       Impact factor: 21.873

6.  Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.

Authors:  Sara Lega; Becky L Phan; Casey J Rosenthal; Julia Gordon; Nichola Haddad; Nanci Pittman; Keith J Benkov; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2019-01-01       Impact factor: 5.325

7.  Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.

Authors:  Gareth J Walker; James W Harrison; Graham A Heap; Michiel D Voskuil; Vibeke Andersen; Carl A Anderson; Ashwin N Ananthakrishnan; Jeffrey C Barrett; Laurent Beaugerie; Claire M Bewshea; Andy T Cole; Fraser R Cummings; Mark J Daly; Pierre Ellul; Richard N Fedorak; Eleonora A M Festen; Timothy H Florin; Daniel R Gaya; Jonas Halfvarson; Ailsa L Hart; Neel M Heerasing; Peter Hendy; Peter M Irving; Samuel E Jones; Jukka Koskela; James O Lindsay; John C Mansfield; Dermot McGovern; Miles Parkes; Richard C G Pollok; Subramaniam Ramakrishnan; David S Rampton; Manuel A Rivas; Richard K Russell; Michael Schultz; Shaji Sebastian; Philippe Seksik; Abhey Singh; Kenji So; Harry Sokol; Kavitha Subramaniam; Anthony Todd; Vito Annese; Rinse K Weersma; Ramnik Xavier; Rebecca Ward; Michael N Weedon; James R Goodhand; Nicholas A Kennedy; Tariq Ahmad
Journal:  JAMA       Date:  2019-02-26       Impact factor: 56.272

8.  Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.

Authors:  Magali Lemaitre; Julien Kirchgesner; Annie Rudnichi; Fabrice Carrat; Mahmoud Zureik; Franck Carbonnel; Rosemary Dray-Spira
Journal:  JAMA       Date:  2017-11-07       Impact factor: 56.272

9.  Effect of IBD medications on COVID-19 outcomes: results from an international registry.

Authors:  Jean-Frederic Colombel; Michael D Kappelman; Ryan C Ungaro; Erica J Brenner; Richard B Gearry; Gilaad G Kaplan; Michele Kissous-Hunt; James D Lewis; Siew C Ng; Jean-Francois Rahier; Walter Reinisch; Flávio Steinwurz; Fox E Underwood; Xian Zhang
Journal:  Gut       Date:  2020-10-20       Impact factor: 31.793
  9 in total
  1 in total

1.  Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).

Authors:  Marla Dubinsky; Adam Cheifetz; Konstantinos Papamichael; Vipul Jairath; Guangyong Zou; Benjamin Cohen; Timothy Ritter; Bruce Sands; Corey Siegel; John Valentine; Michelle Smith; Niels Vande Casteele
Journal:  BMJ Open       Date:  2022-04-01       Impact factor: 2.692
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.